Centauri Therapeutics Limited (Centauri), an immunotherapy company founded by Animatrix Founders LLP and focused on the treatment of infectious diseases, today announced the close of its £24 million GBP (c. 32 million USD) Series A investment round. The funds will support the continued advancement of the Company’s antimicrobial resistance (AMR) research and development, using the Alphamer® platform to identify and progress novel antibacterial candidates through first-in-human trials, for difficult-to-treat infections.